The bill CS/HB 57 2025 seeks to amend Florida's drug laws by introducing xylazine as a controlled substance and expanding the list of illegal substances to include various synthetic cannabinoids and substituted cathinones. It specifically excludes certain FDA-approved xylazine animal drug products from regulation while establishing that the manufacture, importation, distribution, prescribing, or sale of xylazine for human use will not be exempt. The bill also outlines new criminal penalties for trafficking in xylazine, with tiered penalties based on the quantity involved, including mandatory minimum sentences and fines.

In addition to addressing xylazine, the bill enhances penalties for trafficking in dangerous drugs, particularly fentanyl and its analogs, with mandatory minimum sentences that escalate based on the amount involved. It also includes provisions for harsher penalties if drugs are sold to minors or resemble consumer products, aiming to mitigate the risks associated with substance abuse among younger populations. The proposed changes are set to take effect on October 1, 2025, unless specified otherwise.

Statutes affected:
H 57 Filed: 893.13, 893.135
H 57 c1: 893.03, 893.13, 893.135